Stability of cognitive performance in older patients with schizophrenia: An 8-week lest-retest study

被引:47
作者
Harvey, PD
Palmer, BW
Heaton, RK
Mohamed, S
Kennedy, J
Brickman, A
机构
[1] CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[2] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA
[3] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45221 USA
[4] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46204 USA
关键词
D O I
10.1176/appi.ajp.162.1.110
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: It is important to understand the stability of cognitive performance in schizophrenia in order to understand 1) the potential improvements in performance associated with the beneficial effects of cognitive-enhancing medications and 2) the potential variation in performance on cognitive measures that are components of neuroimaging studies. There are several factors that could lead to spurious improvements in cognitive test scores, including practice effects and random test-retest errors. Method: Forty-five older patients with schizophrenia who were receiving conventional antipsychotic medications participated in the study. All subjects completed a comprehensive neuropsychological test battery at baseline and again at an 8-week follow-up evaluation. Results: Performance on all of the cognitive measures was stable over time, as evidenced by significant test-retest correlations, and practice effects were generally absent or minimal. Tests administered with alternate forms were no more temporally stable than tests administered twice with the same form. Very few individual cases had substantial variation at retest across the 22 test scores. From these data, "norms for evaluating change" were developed and described using the reliable change index method. Conclusions: The data suggest that the findings of modest cognitive improvements seen in some prior studies of schizophrenia patients when treated with second-generation antipsychotic medications were probably not due to simple retesting artifacts. At the same time, because of the variance in some of these test-retest performances, relatively substantial changes in performance on the part of individual patients would be required to be clearly interpretable.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 34 条
[1]  
[Anonymous], 1993, The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation
[2]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[3]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[4]  
BENTON A L, 1978, Archives of Neurology, V35, P364
[5]  
Blyer CR, 2000, COGNITIVE FUNCTIONIN, P241
[6]  
COMBLATT BA, 1989, PSYCHIAT RES, V29, P65
[7]   Test-retest reliability and practice effects of Expanded Halstead-Reitan neuropsychological test battery [J].
Dikmen, SS ;
Heaton, RK ;
Grant, I ;
Temkin, NR .
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 1999, 5 (04) :346-356
[8]  
Ferris SH, 1997, ALZ DIS ASSOC DIS, V11, pS1
[9]   A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia [J].
Friedman, JI ;
Adler, DN ;
Howanitz, E ;
Harvey, PD ;
Brenner, G ;
Temporini, H ;
White, L ;
Parrella, M ;
Davis, KL .
BIOLOGICAL PSYCHIATRY, 2002, 51 (05) :349-357
[10]   Guanfacine treatment of cognitive impairment in schizophrenia [J].
Friedman, JI ;
Adler, DN ;
Temporini, HD ;
Kemether, E ;
Harvey, PD ;
White, L ;
Parrella, M ;
Davis, KL .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (03) :402-409